Drug Trial Radar · NCT05586802
Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome
Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Mar 21, 2023
Primary completion
Apr 30, 2027
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- Georgios PapadakisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 16 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study seeks primarily to determine whether modulation of systemic and testicular sex steroids balance by aromatase inhibitors will positively affect the metabolic health and spermatogenesis of men with Klinefelter syndrome (KFS) as compared to the current state of the art for each issue. Secondary objectives of this study are (i) to unravel the heterogeneity of the reproductive and metabolic phenotype of men with KFS by performing a multi-omic analysis in a large cohort at baseline; (ii) to evaluate the efficacy of semaglutide-induced weight loss to achieve metabolic and reproductive benefit in men with Klinefelter syndrome as compared to standard testosterone replacement; (ii) to assess whether addition of hCG to aromatase inhibitors further increases intratesticular testosterone and promotes spermatogenesis in men with KFS.
Conditions
- Klinefelter Syndrome
Interventions
AnastrozoleDrug
This will be an experimental treatment for 26 weeks in Group 1 Arm A and Arm B as well for Group 2 Arm D
SemaglutideDrug
This will be an experimental treatment for 26 weeks in Group 2 Arm E
human chorionic gonadotropinDrug
This will be an experimental treatment for 26 weeks in addition to anastrozole in Group 1 - Arm B
Testosterone gelDrug
This will be an active comparator for 26 weeks in Group 2 - Arm C
Primary outcomes
What the sponsor says the trial is designed to measure.
- Design 1 : sperm retrieval rate at mTESE biopsyTime frame: mTESE biopsy 26 weeks after hormonal intervention
- Design 2 : change in insulin resistance index (HOMA-IR)Time frame: From baseline to week 26 of intervention
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Service of Endocrinology, Diabetes & Metabolism
Lausanne, Switzerland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.